Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Cardone

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
ESMO Open|October 12, 2017
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programmeVincenzo Sforza, Erika Martinelli, Claudia Cardone, et al.
La Radiologia Medica|September 11, 2023
Radiomics and machine learning analysis by computed tomography and magnetic resonance imaging in colorectal liver metastases prognostic assessmentVincenza Granata, Roberta Fusco, Federica De Muzio, et al.
ESMO Open|September 27, 2019
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancerClaudia Cardone, Erika Martinelli, Teresa Troiani, et al.
Oncotarget|May 13, 2015
AXL is an oncotarget in human colorectal cancerErika Martinelli, Giulia Martini, Claudia Cardone, et al.
Clinical Drug Investigation|June 17, 2024
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 TrialErika Martinelli, Davide Ciardiello, Giulia Martini, et al.
ESMO Open|December 7, 2017
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatmentErika Martinelli, Vincenzo Sforza, Claudia Cardone, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 7, 2021
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancerPietro Paolo Vitiello, Giulia Martini, Luigi Mele, et al.
Gastroenterology|April 13, 2017
EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of PatientsSriram Srivatsa, Mariel C Paul, Claudia Cardone, et al.
International Journal of Cancer|July 1, 2023
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trialStefania Napolitano, Davide Ciardiello, Vincenzo De Falco, et al.
Molecular Oncology|July 20, 2019
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancerElena Elez, Chiara Chianese, Enrique Sanz-García, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
ESMO Open|October 12, 2017
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programmeVincenzo Sforza, Erika Martinelli, Claudia Cardone, et al.
La Radiologia Medica|September 11, 2023
Radiomics and machine learning analysis by computed tomography and magnetic resonance imaging in colorectal liver metastases prognostic assessmentVincenza Granata, Roberta Fusco, Federica De Muzio, et al.
ESMO Open|September 27, 2019
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancerClaudia Cardone, Erika Martinelli, Teresa Troiani, et al.
Oncotarget|May 13, 2015
AXL is an oncotarget in human colorectal cancerErika Martinelli, Giulia Martini, Claudia Cardone, et al.
Clinical Drug Investigation|June 17, 2024
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 TrialErika Martinelli, Davide Ciardiello, Giulia Martini, et al.
ESMO Open|December 7, 2017
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatmentErika Martinelli, Vincenzo Sforza, Claudia Cardone, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 7, 2021
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancerPietro Paolo Vitiello, Giulia Martini, Luigi Mele, et al.
Gastroenterology|April 13, 2017
EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of PatientsSriram Srivatsa, Mariel C Paul, Claudia Cardone, et al.
International Journal of Cancer|July 1, 2023
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trialStefania Napolitano, Davide Ciardiello, Vincenzo De Falco, et al.
Molecular Oncology|July 20, 2019
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancerElena Elez, Chiara Chianese, Enrique Sanz-García, et al.
Pageof 4